Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...

Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System FRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...

Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5® Advanced Wound System FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc....